title: Encapsulation of Aβ(1-15) in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes.
abstract: The aim of the present work was to develop an easy, safe and effective vaccine in Balb/c mice using the Aβ(1-15) peptide as immunogen entrapped in PLGA microparticles to reduce the risk of an adverse T cell-mediated response. Aβ(1-15,) which contains the N-terminal antibody epitope of the full Aβ(1-42) peptide was encapsulated in PLGA by a modified solvent evaporation/extraction technique using a double emulsion system. Microparticles were characterized in terms of size distribution (1.22±0.28 μm), encapsulation efficiency (75.05±4.17%), surface associated peptide (59.81±0.96%) and "in vitro" release profile. Balb/c mice were immunized by subcutaneous and intranasal routes with three 30 μg doses of the peptide microencapsulated in PLGA. A solution of the peptide alone and an emulsion in the Freund's adjuvant were administered subcutaneously as control groups. Antibody levels elicited against the toxic Aβ(1-40) fraction in the serum of PLGA microparticles treated groups were higher than that of the peptide alone groups. Our initial results indicate that immunotherapy with Aβ(1-15) loaded PLGA microparticles could be a promising approach for the future development of a safe vaccine against Alzheimer's disease.
authors.affiliation: Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Puras
authors.forename: A
authors.initials: A
authors.lastname: Salvador
authors.forename: M
authors.initials: M
authors.lastname: Igartua
authors.forename: R M
authors.initials: RM
authors.lastname: Hernández
authors.forename: J L
authors.initials: JL
authors.lastname: Pedraz
mesh_terms: D000281:Administration, Intranasal; D000544:Alzheimer Disease / Q000276:immunology / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D000818:Animals; D004334:Drug Administration Schedule; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D004797:Enzyme-Linked Immunosorbent Assay; D018985:Epitopes, B-Lymphocyte / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood*; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000737:chemistry*; D051379:Mice; D008807:Mice, Inbred BALB C; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013499:Surface Properties
chemical_list: D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D004337:Drug Carriers; D018985:Epitopes, B-Lymphocyte; D018984:Epitopes, T-Lymphocyte; D007074:Immunoglobulin G; D010446:Peptide Fragments; C480626:amyloid beta-protein (1-15); D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid